SIGA Technologies (SIGA) AI Stock Analysis

• Market Cap: $582.87M
• Dividend Yield: N/A
• Average Volume (3M): 461.52K
• Price to Earnings (P/E): 7.1
• Beta (1Y): 1.17
• Revenue Growth: -0.85%
• EPS Growth: -13.50%
• Country: US
• Employees: 46
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.09
• Shares Outstanding: 71,606,000
• 10 Day Avg. Volume: 376,632
• 30 Day Avg. Volume: 461,516
• PEG Ratio: -0.57
• Price to Book (P/B): 1.98
• Price to Sales (P/S): 3.09
• P/FCF Ratio: 8.79
• Enterprise Value/Market Cap: 0.49
• Enterprise Value/Revenue: 1.66
• Enterprise Value/Gross Profit: 2.18
• Enterprise Value/Ebitda: 3.04
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: $6.50 ▼(-0.31% Downside)

SIGA Technologies' strong financial performance and undervaluation are significant positives, but technical indicators suggest bearish momentum. The earnings call provided a balanced view with growth potential and challenges, resulting in a moderate overall score.

Positive Factors

Strong Financial Position

A strong cash position and no debt provide SIGA with the flexibility to invest in growth opportunities and manage risks, supporting long-term stability.

Significant Product Revenue Growth

The growth in product sales indicates strong demand and effective market penetration, which can drive sustained revenue growth over the long term.

Pipeline Advancements

Advancements in the pipeline, including new indications, enhance SIGA's product offerings and potential market reach, supporting future revenue streams.

Negative Factors

Stagnant Revenue Growth

Stagnant revenue growth may indicate market saturation or competitive pressures, potentially limiting future expansion and profitability.

Decline in Operating Cash Flow

A significant decline in operating cash flow could hinder the company's ability to fund operations and invest in growth, impacting long-term financial health.

EMA Concerns About TPOXX

Regulatory concerns from the EMA could affect TPOXX's market acceptance and sales in Europe, impacting international revenue growth potential.

SIGA Technologies Business Overview & Revenue Model

Company Description

SIGA Technologies, Inc. is a biotechnology company focused on developing and commercializing antiviral therapeutics for serious infectious diseases. The company is primarily engaged in the research, development, and commercialization of small molecule drugs for the treatment of viral infections, with a strong emphasis on addressing bioterrorism threats and emerging infectious diseases. SIGA’s core products include TPOXX (tecovirimat), an antiviral medication approved for the treatment of smallpox, as well as ongoing research into other antiviral candidates targeting various viral pathogens.

How the Company Makes Money

SIGA Technologies generates revenue primarily through the sale of its antiviral product, TPOXX, which is sold to government agencies, including the U.S. Department of Health and Human Services and the Department of Defense, as part of the U.S. Strategic National Stockpile. The company also earns revenue from contracts and grants related to research and development activities from governmental and non-governmental organizations. Additionally, SIGA may explore partnerships and collaborations with other pharmaceutical companies or organizations to expand its product offerings and reach, further contributing to its earnings.

SIGA Technologies Financial Statement Overview

Summary

SIGA Technologies demonstrates strong financial health with high profitability, a robust balance sheet with no debt, and sufficient cash flow generation. However, stagnant revenue growth and a decline in operating cash flow are areas to monitor closely for future financial performance.

Income Statement

SIGA Technologies has shown strong profitability with consistent gross and net profit margins over the years. The gross profit margin remains high at 100% in the latest year, indicating effective cost management. The net profit margin, although slightly reduced from the previous year, is still robust at 42.7%. However, the revenue growth has been stagnant, with a slight decrease of 0.9% from the prior year, which could suggest a plateau in sales expansion.

Balance Sheet

The company maintains a solid financial position with no debt, reflected in a debt-to-equity ratio of 0. The equity ratio is strong at 88.3%, indicating financial stability and a low-risk profile. Return on equity (ROE) is healthy at 27.4%, showcasing effective use of equity financing to generate profits. The absence of debt reduces financial risk significantly.

Cash Flow

Operating cash flow has decreased by 48.6% compared to the previous year, which could be a concern if the trend continues. However, free cash flow remains positive, indicating the company can cover its capital expenditures. The free cash flow to net income ratio is satisfactory, showing that profits are backed by cash generation. The decline in cash flow growth rate is a potential risk area.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	172.25M	138.72M	139.92M	110.78M	133.67M	124.96M
Gross Profit	131.40M	107.43M	122.09M	100.34M	117.07M	99.22M
EBITDA	94.29M	70.52M	84.16M	43.22M	89.62M	77.06M
Net Income	74.47M	59.21M	68.07M	33.90M	69.45M	56.34M
Balance Sheet
Total Assets	231.60M	244.34M	254.35M	195.04M	214.73M	149.83M
Cash, Cash Equivalents and Short-Term Investments	171.96M	155.40M	150.15M	98.79M	103.14M	117.89M
Total Debt	914.55K	546.82K	564.01K	528.17K	466.83K	449.94K
Total Liabilities	28.12M	28.53M	57.49M	24.88M	40.41M	20.04M
Stockholders Equity	203.48M	215.80M	196.86M	170.16M	174.31M	129.79M
Cash Flow
Free Cash Flow	116.31M	48.72M	94.78M	41.61M	11.44M	71.50M
Operating Cash Flow	116.64M	48.76M	94.80M	41.61M	11.49M	71.52M
Investing Cash Flow	-332.31K	-42.45K	-21.69K	0.00	-50.62K	-15.50K
Financing Cash Flow	-43.62M	-43.46M	-43.42M	-45.96M	-26.20M	-114.60M

SIGA Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIGA, the sentiment is Negative. The current price of 6.52 is above the 20-day moving average (MA) of 6.06, below the 50-day MA of 7.29, and below the 200-day MA of 6.82, indicating a neutral trend. The MACD of -0.26 indicates Negative momentum. The RSI at 49.96 is Neutral, neither overbought nor oversold. The STOCH value of 83.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SIGA.

SIGA Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIGA	73 Outperform	$582.87M	7.09	39.94%	―	-0.85%	-13.50%
DVAX	70 Outperform	$1.28B	―	-7.14%	―	26.73%	-310.39%
EBS	68 Neutral	$610.28M	8.93	13.92%	―	-29.91%	―
ESPR	56 Neutral	$915.61M	―	―	―	2.83%	13.61%
AQST	56 Neutral	$744.22M	―	―	―	-26.32%	-56.54%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORGO	50 Neutral	$590.14M	―	0.30%	―	2.24%	-67.56%

SIGA Technologies Corporate Events

SIGA Technologies’ Earnings Call Highlights Growth and Challenges

The recent earnings call for SIGA Technologies highlighted a generally positive sentiment, underscored by the company’s strong financial standing and growth in product sales. The call conveyed optimism driven by ongoing government contracts and international sales prospects. However, it also acknowledged challenges such as possible delays from a government shutdown, inquiries from the EMA, and inherent quarterly revenue fluctuations.

SIGA Technologies Reports Q3 2025 Financial Results

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company specializing in the development of antiviral medicines to combat infectious diseases, with a primary focus on orthopoxviruses. The company is known for its flagship product, TPOXX, which is approved for the treatment of smallpox and other related diseases in various countries.